NeuroDerm (NDRM)

[stocktrademan]

NDRM buy 28.85









normal chart




log chart

[AHoldUp]

Oppenheimer upgraded Neuroderm Ltd (NASDAQ: NDRM) from Perform to Outperform with a price target of $42.00, sees as potential takeover.

"While the asset still faces a certain level of clinical and regulatory risk, we believe ND0612 is becoming sufficiently de-risked at this point to attract a potential M&A suitor. Our view is supported by recent reports stating that NDRM has retained a financial advisor for the possible sale of the company, according to Bloomberg."

https://www.streetinsider.com/Analyst+Comments/Oppenheimer+Upgrades+Neuroderm+Ltd+%28NDRM%29+to+Outperform%3B+Alleged+Takeover+Discussions+Pump+New+Life+into+ND0612/13009512.html

[AHoldUp]

NDRM (Neuroderm) $ 70.00 Price Target

https://www.streetinsider.com/Analyst+Comments/Neuroderm+Ltd+%28NDRM%29+PT+Raised+to+%2470+at+Cowen%3B+Could+Transform+Late+Stage+Parkinsons+Care/12615650.html

"The current valuation is dramatically understated."

[AHoldUp]

NDRM $ 42.00 price target

https://www.streetinsider.com/Analyst+Comments/NeuroDerm+%28NDRM%29%3A+Investor+Event+Confirms+ND0612+Is+On+Track+-+Jefferies/12803977.html

[AHoldUp]

Well, seems about time to reanimate this board. This NDRM stock is definitly going places. Up north :)

Any number based predictions of stockprice by end 2017?

THX

[magness]

Look at $NDRM. Fabulous day on topical cream. Glad to own it!Q

[stocktrademan]

$NDRM recent news/filings

bullish
higher highs, higher lows uptrend

## source: finance.yahoo.com

Thu, 06 Aug 2015 12:30:00 GMT ~ Neuroderm Ltd Earnings Call scheduled for 8:30 am ET today


read full: http://biz.yahoo.com/cc/3/146143.html
*********************************************************

Thu, 06 Aug 2015 11:00:00 GMT ~ NeuroDerm Announces Second Quarter 2015 Financial Results and Provides Corporate Update

[GlobeNewswire] - REHOVOT, Israel -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ...

read full: http://finance.yahoo.com/news/neuroderm-announces-second-quarter-2015-110000732.html
*********************************************************

Thu, 30 Jul 2015 11:00:00 GMT ~ NeuroDerm to Host Second Quarter 2015 Financial Results Conference Call on August 6, 2015

[GlobeNewswire] - REHOVOT, Israel -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results ...

read full: http://finance.yahoo.com/news/neuroderm-host-second-quarter-2015-110000419.html
*********************************************************

Tue, 21 Jul 2015 15:44:24 GMT ~ NeuroDerm Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

[GlobeNewswire] - REHOVOT, Israel -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the closing of its public offering of ...

read full: http://finance.yahoo.com/news/neuroderm-ltd-announces-closing-public-154424108.html
*********************************************************

Mon, 20 Jul 2015 15:04:03 GMT ~ Can the Rally in NeuroDerm (NDRM) Shares Continue? - Tale of the Tape


read full: http://finance.yahoo.com/news/rally-neuroderm-ndrm-shares-continue-150403904.html
*********************************************************

$NDRM charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NDRM company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NDRM/company-info
Ticker: $NDRM
OTC Market Place: Not Available
CIK code: not found
Company name: NeuroDerm Ltd.
Incorporated In:

$NDRM share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$NDRM extra dd links

Company name: NeuroDerm Ltd.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NDRM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NDRM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NDRM+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NDRM/news - http://finance.yahoo.com/q/h?s=NDRM+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NDRM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NDRM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NDRM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NDRM
DTCC (dtcc.com): http://search2.dtcc.com/?q=NeuroDerm+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=NeuroDerm+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=NeuroDerm+Ltd.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NDRM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NDRM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NDRM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NDRM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NDRM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NDRM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NDRM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NDRM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NDRM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NDRM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NDRM+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NDRM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NDRM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NDRM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NDRM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NDRM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NDRM/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NDRM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NDRM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NDRM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NDRM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NDRM



$NDRM DD Notes ~ http://www.ddnotesmaker.com/NDRM

[JRT]

Slow steady ticks up on light volume. I believe this is an insider gathering shares while trying to not call any attention to the stock. Seems that buys it up, dumps it down a touch and than buys a few more. Thoughts anyone?

[John-Knee]

NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment.
05/08/2015 @ 7:00AM

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, the company's primary product candidates, that are based on proprietary, subcutaneously-delivered Levodopa/Carbidopa (LD/CD) liquid formulation, for the treatment of Parkinson's disease. The hold was lifted after the FDA reviewed additional information related to the product candidates' delivery devices. U.S. clinical development of these product candidates is therefore cleared to proceed in the second half of 2015.
"Having lifted the clinical hold in the first half of 2015 means that our U.S. clinical development program of ND0612H and ND0612L is proceeding on track," said Oded Lieberman, PhD, CEO of NeuroDerm. "Parkinson's patients have been hoping for a less invasive, non-surgical alternative that can deliver levodopa continuously. We remain committed to the execution of our plan to bring these product candidates to the market as soon as possible, and to make a significant impact on the lives of Parkinson's patients."

In June 2014, the FDA placed a hold on the U.S. clinical development of ND0612H and ND0612L, requesting additional information on the accuracy, safety, and compatibility of the devices used to deliver the drug. The company completed the required compatibility study and submitted the requested additional information to the FDA. Following the FDA's decision to lift the clinical hold, the company's U.S. clinical development program is now cleared to proceed, with several studies anticipated to commence in the second half of 2015.

About Parkinson's Disease

Parkinson's disease is a progressive neurodegenerative illness characterized by reduced dopamine in the brain, resulting in a debilitating decrease in the patient's motor and non-motor functions. Its symptoms, such as trembling in the extremities and face, slowness of movement and impaired balance and coordination, worsen over time and gravely impact the patient's quality of life. As the disease progresses, these symptoms become more severe, resulting in debilitating periods of decreased motor and non-motor functions, also referred to as "off" time. In addition, mainly as a result of excessive/intermittent oral doses of levodopa aimed at treating the "off" time, some patients experience involuntary movements, or dyskinesia. The "off" time and dyskinesia affect the majority of Parkinson's disease patients and interfere with day-to-day functions, causing patients to become severely disabled. Continuous administration of levodopa has been shown to effectively treat motor fluctuations in Parkinson's disease patients, however, a convenient route of continuous administration has not been introduced to date.

About Levodopa

Oral administration of LD/CD is regarded as the "gold standard" treatment for patients suffering from Parkinson's disease. Levodopa crosses into the brain and converts into dopamine to complement the reduced brain-dopamine levels. Virtually all patients diagnosed with Parkinson's disease will require levodopa at some point over the course of their treatment for the disease, and 70% to 80% of patients receive the drug at any given point in time. However, levodopa is limited by its short half-life. Approximately three to four hours after a single dose, almost none of the drug remains in the plasma and patients are required to take multiple LD/CD doses daily. This results in sharp fluctuations in levodopa levels which are associated with erratic "off" and "on" periods experienced by many patients. In addition, levodopa suffers from low absorption when administered orally, with only about 30% of the levodopa entering the blood stream. Continuous levodopa administration can overcome this limitation, but steady levodopa delivery can currently only be achieved after undergoing an invasive surgical procedure whereby a tube is permanently implanted into the duodenum, the upper part of the small intestine.

ND0612H, ND0612L

ND0612H and ND0612L are designed to significantly reduce motor complications in Parkinson's disease patients through continuous, subcutaneous delivery of LD/CD. Recently completed phase II trials demonstrated that ND0612L maintained steady, therapeutic levodopa plasma concentrations that were associated with major improvements in several clinical parameters including "off time" reductions when added to optimized oral standard of care. ND0612H, intended for severe Parkinson's disease patients, was shown to reach even higher levodopa steady plasma levels, indicating that it may provide an effective therapy alternative to current treatments requiring surgery such as deep brain stimulation and DuoDopa/Duopa®.

About NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. In Parkinson's disease, the company has four product candidates in different stages of development which offer a solution for almost every Parkinson's disease patient from the moderate to the very severe stage of the disease. The company has developed a line of LD/CD product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD line of product candidates includes: ND0612L and ND0612H, delivered subcutaneously, for moderate and for advanced Parkinson's disease patients, respectively, and ND0680 for a subset of severe Parkinson's disease patients whose symptoms have advanced to a highly advanced stage, requiring even higher doses of LD/CD. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from severe Parkinson's disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.

[KingDMC]

NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment o...

Source: GlobeNewswire Inc.

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, the company's primary product candidates, that are based on proprietary, subcutaneously-delivered Levodopa/Carbidopa (LD/CD) liquid formulation, for the treatment of Parkinson's disease. The hold was lifted after the FDA reviewed additional information related to the product candidates' delivery devices. U.S. clinical development of these product candidates is therefore cleared to proceed in the second half of 2015.
"Having lifted the clinical hold in the first half of 2015 means that our U.S. clinical development program of ND0612H and ND0612L is proceeding on track," said Oded Lieberman, PhD, CEO of NeuroDerm. "Parkinson's patients have been hoping for a less invasive, non-surgical alternative that can deliver levodopa continuously. We remain committed to the execution of our plan to bring these product candidates to the market as soon as possible, and to make a significant impact on the lives of Parkinson's patients."

In June 2014, the FDA placed a hold on the U.S. clinical development of ND0612H and ND0612L, requesting additional information on the accuracy, safety, and compatibility of the devices used to deliver the drug. The company completed the required compatibility study and submitted the requested additional information to the FDA. Following the FDA's decision to lift the clinical hold, the company's U.S. clinical development program is now cleared to proceed, with several studies anticipated to commence in the second half of 2015.

[John-Knee]

Research analysts at Jefferies Group assumed coverage on shares of Neuroderm (NASDAQ:NDRM) in a report released on Thursday. The firm set a “buy” rating and a $21.00 price target on the stock. Jefferies Group’s price objective points to a potential upside of 57.30% from the stock’s previous close.

Neuroderm (NASDAQ:NDRM) opened at 13.35 on Thursday. Neuroderm has a 52-week low of $5.67 and a 52-week high of $19.07. The stock’s 50-day moving average is $13. and its 200-day moving average is $11.. The company’s market cap is $226.90 million.

Neuroderm (NASDAQ:NDRM) last issued its quarterly earnings data on Thursday, April 2nd. The company reported ($2.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.35) by $2.20. On average, analysts predict that Neuroderm will post $-1.52 earnings per share for the current fiscal year.

Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (NASDAQ:NDRM) disorders. It develops product candidates for the treatment of Parkinson’s disease and cognition.

[RealGenius]

Breaking out of downtrend / wedge. Abstract for AAN looks good. Will present on Apr 20.

[JRT]

NDRM up nearly 7% today

[JRT]

Is news coming? Nice move all of a sudden

[Jackassery]

Thoughts on this?

[willmakeitrain]

***pennant formation*** #NDRM-back-on watch

[Ice86]

Time to get back in

[sprot]

Will not judge this Co. Think they do well, but always do your DD and try to read a lot which concernes your investments.
May be interesting for NDRM followers.

http://finance.yahoo.com/news/impaxs-parkinsons-drug-gets-fda-131741494.html

[KingDMC]

HAHA you and me both! $19 PT upgrade is like to see it hit that.

[JRT]

Couldn't stay away. It just keeps pulling me back. lol

[KingDMC]

I agree with that

[smul]

goodmorning,
today it could touch 20'sss

[desidude420]

If this don't recover now it's goin to drop bad!!!! Jmo

[KingDMC]

Oppenheimer raised PT from $18 to $19.

http://tickerreport.com/banking-finance/379791/neuroderm-price-target-increased-to-19-00-by-analysts-at-oppenheimer-nasdaqndrm/

[KingDMC]

Don't know about $30, but most certainly $20....

[Ice86]

Very bullish, maybe $30 :)?

[desidude420]

This may end up red today

[TheFinalCD]

SEE WHAT WE MISSED TODAY

[KingDMC]

Nice call

[Ice86]

Time to get back in

[Ice86]

Load here

[KingDMC]

Nice hold man! Real nice.

[JRT]

Out @ 15. NDRM is the gift that just keeps giving.

[KingDMC]

Damn I sept on this bounce.....

[JRT]

Nice bounce so far today

[beambe]

Pipeline-$$$
.

[beambe]

VOLUME

[JRT]

Got the 13s. Guess I should have asked for 12s the way it is looking

[KingDMC]

Looking good so far.

[JRT]

Been waiting to avg down with 13. Not going to happen. I'm looking for 22 Monday.

[JRT]

Thanks for your concern but I sold @ over 18 and bought the dip. 2015 potential is unlimited. Buy outs, new results, unlimited possibilities. We'll talk again in 2016. weeeeeeeeeeeeeeeeee

[JRT]

Guess we'll see. I didn't expect it until Monday. I might take 13 before this is all over.

[Asher78]

lol how'd that work out

[beambe]

[beambe]

[TheFinalCD]

I THINK NDRM HAS A BETTER CHANCE OF BOUNCING THAN NRX, JUST BECAUSE IT BEING A PARKINSONS DRUG=
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109501527

NRX= DIABETIC NEPHROPATHY


BUT WTH WOULD I KNOW,,,,NOT BEING IN THE MEDICAL FIELD (LOL)


AND OBVIOSLY BOTH UP A CRAZY AMOUNT, AND MAY NEED TO FIND A MORE REASONABLE BASE?

GREAT LIQUIDITY AND SWING TRADERS FOR SURE


JUST GOT TO BE ON THE RIGHT SIDE OF THE TRADES

[KingDMC]

Definitely late trades posting lol. Someone has to be out of their mind to pay that with the stock down 23%

[MONEYMADE]

I WONDER IF THIS POS WILL BOUNCE BACK FROM LOW TEENS! EASY MONEY...

[JRT]

I seen that and was going to ask if they were T trades from earlier in the day.

[TheFinalCD]

$18-$19 A/H PRINTS


LOL